Folger Nolan Fleming Douglas Capital Management Inc. Sells 100 Shares of Danaher Co. (NYSE:DHR)

Folger Nolan Fleming Douglas Capital Management Inc. lessened its stake in Danaher Co. (NYSE:DHRGet Rating) by 2.6% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,720 shares of the conglomerate’s stock after selling 100 shares during the quarter. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Danaher were worth $943,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. GHP Investment Advisors Inc. purchased a new stake in shares of Danaher during the first quarter valued at approximately $26,000. Lloyd Advisory Services LLC. purchased a new stake in shares of Danaher during the first quarter valued at approximately $26,000. Lansing Street Advisors purchased a new stake in shares of Danaher during the first quarter valued at approximately $34,000. American National Bank purchased a new stake in shares of Danaher during the first quarter valued at approximately $35,000. Finally, Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. purchased a new stake in shares of Danaher during the first quarter valued at approximately $35,000. Institutional investors own 77.27% of the company’s stock.

Analysts Set New Price Targets

DHR has been the subject of a number of recent research reports. Royal Bank of Canada raised their target price on Danaher from $317.00 to $318.00 and gave the stock an “outperform” rating in a research report on Friday, September 16th. Benchmark decreased their target price on Danaher from $345.00 to $325.00 and set a “buy” rating for the company in a research report on Tuesday. Robert W. Baird raised their target price on Danaher from $319.00 to $325.00 in a research report on Friday, July 22nd. Credit Suisse Group initiated coverage on Danaher in a research report on Wednesday, August 24th. They issued an “outperform” rating and a $340.00 target price for the company. Finally, Evercore ISI decreased their target price on Danaher from $320.00 to $280.00 and set an “outperform” rating for the company in a research report on Tuesday, July 5th. One investment analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $321.75.

Danaher Price Performance

NYSE:DHR traded down $3.90 during trading hours on Friday, hitting $262.53. 107,851 shares of the company’s stock traded hands, compared to its average volume of 2,203,832. The firm has a market cap of $190.98 billion, a P/E ratio of 31.06, a P/E/G ratio of 1.29 and a beta of 0.88. Danaher Co. has a 52 week low of $233.71 and a 52 week high of $331.68. The business’s fifty day simple moving average is $280.99 and its two-hundred day simple moving average is $269.91. The company has a quick ratio of 1.32, a current ratio of 1.75 and a debt-to-equity ratio of 0.45.

Danaher (NYSE:DHRGet Rating) last posted its quarterly earnings data on Thursday, July 21st. The conglomerate reported $2.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.35 by $0.41. Danaher had a return on equity of 18.57% and a net margin of 20.61%. The firm had revenue of $7.75 billion during the quarter, compared to analysts’ expectations of $7.29 billion. During the same period in the prior year, the business earned $2.46 EPS. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. On average, research analysts anticipate that Danaher Co. will post 10.4 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 28th. Shareholders of record on Friday, September 30th will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 0.38%. The ex-dividend date of this dividend is Thursday, September 29th. Danaher’s payout ratio is 11.78%.

Insider Buying and Selling at Danaher

In other Danaher news, CEO Rainer Blair sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $300.00, for a total transaction of $7,500,000.00. Following the transaction, the chief executive officer now owns 79,739 shares in the company, valued at approximately $23,921,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Danaher news, CEO Rainer Blair sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $300.00, for a total transaction of $7,500,000.00. Following the transaction, the chief executive officer now owns 79,739 shares in the company, valued at approximately $23,921,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Walter G. Lohr sold 3,906 shares of the company’s stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $273.84, for a total value of $1,069,619.04. Following the completion of the sale, the director now owns 12,115 shares in the company, valued at approximately $3,317,571.60. The disclosure for this sale can be found here. Insiders sold 40,906 shares of company stock valued at $11,823,179 in the last 90 days. Insiders own 11.20% of the company’s stock.

Danaher Company Profile

(Get Rating)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.

See Also

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRGet Rating).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.